Edmond de Rothschild Holding’s Avadel Pharmaceuticals AVDL Stock Holding History

Edmond de Rothschild Holding’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$27K	–	726
2020 Q4	$27K	Buy	+4,000	New	+$25K	﹤0.01%	585
2019 Q1	–	Sell	-5,300	Closed	-$14K	–	613
2018 Q4	$14K	Hold	5,300	–	–	﹤0.01%	623
2018 Q3	$23K	Hold	5,300	–	–	﹤0.01%	663
2018 Q2	$32K	Hold	5,300	–	–	﹤0.01%	639
2018 Q1	$39K	Buy	5,300 +2,650	+100%	+$23.3K	﹤0.01%	643
2017 Q4	$22K	Buy	+2,650	New	+$24.9K	﹤0.01%	707
2017 Q2	–	Sell	-4,000	Closed	-$39K	–	812
2017 Q1	$39K	Hold	4,000	–	–	﹤0.01%	673
2016 Q4	$42K	Hold	4,000	–	–	﹤0.01%	668
2016 Q3	$50K	Hold	4,000	–	–	﹤0.01%	663
2016 Q2	$43K	Hold	4,000	–	–	﹤0.01%	662
2016 Q1	$44K	Hold	4,000	–	–	﹤0.01%	650
2015 Q4	$49K	Sell	4,000 -86,798	-96%	-$1.35M	﹤0.01%	634
2015 Q3	$1.48M	Buy	90,798 +45,398	+100%	+$1,000K	0.04%	241
2015 Q2	$962K	Buy	+45,400	New	+$814K	0.02%	295

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Edmond de Rothschild Holding's AVDL Position: Q1 2021 in Review

Edmond de Rothschild Holding sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 4,000 shares — an estimated $27K sold.

Edmond de Rothschild Holding first reported a position in AVDL in Q2 2015 and held it in 14 quarters. The position peaked at $1.48M in Q3 2015. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

Edmond de Rothschild Holding reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Edmond de Rothschild Holding sold 4,000 Avadel Pharmaceuticals shares in Q1 2021, an estimated $27K.
Edmond de Rothschild Holding first reported a position in Avadel Pharmaceuticals in Q2 2015 and held it in 14 quarters.
Edmond de Rothschild Holding's Avadel Pharmaceuticals position peaked at $1.48M in Q3 2015.
76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on Edmond de Rothschild Holding's 13F filing for Q1 2021, filed 17 May 2021.